Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21399871 | 1.00 | NFE2L2 (0.43) | NFE2L2RAPGEF4AHRPTGS1NOTUM | |
| SCHEMBL16829667 | 0.87 | NFE2L2 (0.40) | NFE2L2RAPGEF4AHRPTGS1 | |
| SCHEMBL16829670 | 0.87 | NFE2L2 (0.40) | NFE2L2RAPGEF4AHRPTGS1 | |
| SCHEMBL13243702 | 0.87 | NFE2L2 (0.40) | NFE2L2RAPGEF4AHRPTGS1 | |
| SCHEMBL13874967 | 0.82 | NFE2L2 (0.59) | NFE2L2RAPGEF4AHRPTGS1CYP1A1 | |
| SCHEMBL17147392 | 0.81 | NFE2L2 (0.41) | NFE2L2RAPGEF4AHRPTGS1NOTUM | |
| SCHEMBL16957514 | 0.80 | PTGS1 (0.37) | NFE2L2AHRPTGS1PDK2 | |
| SCHEMBL25870288 | 0.79 | GABBR2 (0.42) | NFE2L2RAPGEF4AHRPTGS1NOTUM | |
| SCHEMBL14202356 | 0.78 | PTGS1 (0.55) | NFE2L2PTGS1HTTCYP1A1CYP1B1 | |
| SCHEMBL18195370 | 0.78 | NFE2L2 (0.39) | NFE2L2RAPGEF4AHRPTGS1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | CETP, MTTP, LCAT | NFE2L2 3584/4885RAPGEF4 4421/4885AHR 3975/4885 |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | CETP, MTTP, LCAT | NFE2L2 3584/4885RAPGEF4 4421/4885AHR 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.